153 related articles for article (PubMed ID: 21102360)
41. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
[TBL] [Abstract][Full Text] [Related]
42. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
43. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
44. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
[TBL] [Abstract][Full Text] [Related]
45. Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
Kim KB; Sanguino AM; Hodges C; Papadopoulos NE; Eton O; Camacho LH; Broemeling LD; Johnson MM; Ballo MT; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Prieto VG; Bedikian AY
Cancer; 2004 Apr; 100(7):1478-83. PubMed ID: 15042682
[TBL] [Abstract][Full Text] [Related]
46. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
47. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
[TBL] [Abstract][Full Text] [Related]
48. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
Buzaid AC; Legha SS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
[TBL] [Abstract][Full Text] [Related]
49. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.
Proebstle TM; Fuchs T; Scheibenbogen C; Sterry W; Keilholz U
Melanoma Res; 1998 Dec; 8(6):557-63. PubMed ID: 9918418
[TBL] [Abstract][Full Text] [Related]
50. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
51. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
[TBL] [Abstract][Full Text] [Related]
52. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
53. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
Buzaid AC; Ali-Osman F; Akande N; Grimm EA; Lee JJ; Bedikian A; Eton O; Papadopoulos N; Plager C; Legha SS; Benjamin RS
Melanoma Res; 1998 Apr; 8(2):145-8. PubMed ID: 9610867
[TBL] [Abstract][Full Text] [Related]
54. Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
Boasberg PD; O'Day SJ; Kristedja TS; Martin M; Wang H; Deck R; Shinn K; Ames P; Tamar B; Petrovich Z
Oncology; 2003; 64(4):328-35. PubMed ID: 12759528
[TBL] [Abstract][Full Text] [Related]
55. Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
Hau HM; Tautenhahn HM; Schoenberg MB; Atanasov G; Wiltberger G; Morgül MH; Uhlmann D; Seitz AT; Simon JC; Schmelzle M; Bartels M
Anticancer Res; 2014 Nov; 34(11):6633-9. PubMed ID: 25368268
[TBL] [Abstract][Full Text] [Related]
56. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract][Full Text] [Related]
57. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
58. [Experiences with therapy of stage IV metastatic malignant melanoma with "Legha Protocol" polychemoimmunotherapy].
Fischer B; Knop J; Enk AH
Hautarzt; 2002 Jun; 53(6):393-9. PubMed ID: 12132295
[TBL] [Abstract][Full Text] [Related]
59. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
Håkansson A; Håkansson L; Gustafsson B; Krysander L; Rettrup B; Ruiter D; Bernsen MR
Melanoma Res; 2003 Aug; 13(4):401-7. PubMed ID: 12883367
[TBL] [Abstract][Full Text] [Related]
60. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.
Håkansson A; Gustafsson B; Krysander L; Hjelmqvist B; Rettrup B; Håkansson L
Br J Cancer; 2001 Dec; 85(12):1871-7. PubMed ID: 11747328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
